NCT01787383View on ClinicalTrials.gov

A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Actinic Keratosis
Interventions
DRUG

Ingenol mebutate gel 0.05 %

Ingenol mebutate gel 0.05 % (Picato®) on trunk/extremities either applied simultaneously or sequentially

DRUG

Ingenol mebutate gel 0.015 %

Ingenol mebutate gel 0.015 % (Picato®) on face/scalp either applied simultaneously or sequentially

Trial Locations (1)

41124

Clinica Dermatologica dell'Università di Modena e Reggio Emilia, Modena

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY